Due to cancer risk, CINs are divided into two categories: low-grade intraepithelial lesions (LSILs, formerly called CIN I and p16-negative CIN II) and high-grade intraepithelial lesions (HSILs, formerly called CIN III and p16-positive CIN II). This evidence concerns the gene CDKN2A and cancer.